Jan M NovÃ;k

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/260652/publications.pdf

Version: 2024-02-01

| | 840776 | 454955 |
|----------------|--------------|------------------------------|
| 982 | 11 | 30 g-index |
| citations | h-index | g-index |
| | | |
| | | |
| 20 | 20 | 1.450 |
| 39 | 39 | 1459 |
| docs citations | times ranked | citing authors |
| | | |
| | citations 39 | 982 11 citations h-index 39 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 43-56. | 10.7 | 448 |
| 2 | Do e-Cigarettes Have the Potential to Compete With Conventional Cigarettes?. Chest, 2013, 144, 1609-1614. | 0.8 | 79 |
| 3 | Chromosomal Abnormalities and Prognosis in <i>NPM1</i> Hutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. Journal of Clinical Oncology, 2019, 37, 2632-2642. | 1.6 | 77 |
| 4 | Mechanism of regulation of autoimmunity by iNKT cells. Cytokine, 2011, 53, 263-270. | 3.2 | 73 |
| 5 | First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica, 2022, 107, 2108-2120. | 3.5 | 53 |
| 6 | Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. JMIR MHealth and UHealth, 2020, 8, e16043. | 3.7 | 31 |
| 7 | Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation. Clinical and Experimental Medicine, 2016, 16, 529-537. | 3.6 | 20 |
| 8 | Successful early use of antiâ€SARSâ€CoVâ€2 monoclonal neutralizing antibodies in SARSâ€CoVâ€2 infected hematological patients – A Czech multicenter experience. Hematological Oncology, 2022, 40, 280-286. | 1.7 | 19 |
| 9 | 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer Journal, 2021, 11, 163. | 6.2 | 17 |
| 10 | Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood, 2022, 140, 285-289. | 1.4 | 15 |
| 11 | Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab. Clinical and Experimental Medicine, 2023, 23, 371-379. | 3.6 | 14 |
| 12 | Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na \tilde{A} ve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles. Blood, 2019, 134, 2591-2591. | 1.4 | 12 |
| 13 | Data Visualization for Chronic Neurological and Mental Health Condition Self-management: Systematic Review of User Perspectives. JMIR Mental Health, 2022, 9, e25249. | 3.3 | 12 |
| 14 | Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 71. | 6.2 | 12 |
| 15 | Comparison of Munich Chronotype Questionnaire (MCTQ) and Morningness-Eveningness Questionnaire (MEQ) Czech version. Chronobiology International, 2020, 37, 1591-1598. | 2.0 | 11 |
| 16 | Potential role of invariant natural killer T cells in outcomes of acute myocardial infarction. International Journal of Cardiology, 2015, 187, 663-665. | 1.7 | 7 |
| 17 | Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leukemia Research, 2019, 79, 17-21. | 0.8 | 7 |
| 18 | Realâ€world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <scp>GO LLEAR</scp> Study by the Czech <scp>CLL</scp> Study Group. Hematological Oncology, 2020, 38, 509-516. | 1.7 | 7 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Insufficient Physical Fitness and Deficits in Basic Eating Habits in Normal-Weight Obese Children Are Apparent from Pre-School Age or Sooner. Nutrients, 2021, 13, 3464. | 4.1 | 7 |
| 20 | Patients' Measurement Priorities for Remote Measurement Technologies to Aid Chronic Health Conditions: Qualitative Analysis. JMIR MHealth and UHealth, 2020, 8, e15086. | 3.7 | 7 |
| 21 | The relationship between adolescent obesity and pelvis dimensions in adulthood: a retrospective longitudinal study. PeerJ, 2020, 8, e8951. | 2.0 | 7 |
| 22 | Seroprevalence of Larval Toxocarosis in the Czech Republic. Acta Parasitologica, 2020, 65, 68-76. | 1.1 | 6 |
| 23 | Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks. Scientific Reports, 2021, 11, 322. | 3.3 | 6 |
| 24 | Reliability and Validity of the Czech Version of the Pittsburgh Sleep Quality Index in Patients with Sleep Disorders and Healthy Controls. BioMed Research International, 2021, 2021, 1-9. | 1.9 | 6 |
| 25 | Secular Changes in Body Build and Body Composition in Czech Preschool Children in the Context of Latent Obesity. Children, 2021, 8, 18. | 1.5 | 6 |
| 26 | Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells. Clinical and Experimental Medicine, 2013, 13, 229-237. | 3.6 | 4 |
| 27 | Clinical case: idelalisib-induced immunoglobulin flare. Immunopharmacology and Immunotoxicology, 2017, 39, 251-252. | 2.4 | 3 |
| 28 | Endobronchial involvement as an extremely rare manifestation of the <scp>W</scp> aldenström's disease. Clinical Respiratory Journal, 2018, 12, 816-819. | 1.6 | 3 |
| 29 | Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 106-113. | 0.4 | 2 |
| 30 | The repeatability of the instrumented timed Up & Description (and parkinsona) and Biomedical Engineering, 2020, 40, 363-377. | 5.9 | 2 |
| 31 | Antigenic Proteins from the Excretory–Secretory Products of Toxocara canis Larvae and Evaluation of Their Potential for Immunodiagnostics of Larval Toxocarosis. Acta Parasitologica, 2022, 67, 705-713. | 1.1 | 2 |
| 32 | Key Drivers and Facilitators of the Choice to Use mHealth Technology in People With Neurological Conditions: Observational Study. JMIR Formative Research, 2022, 6, e29509. | 1.4 | 2 |
| 33 | Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35. | 1.4 | 1 |